Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 58.07

+2.1%

10:32 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: IRWIN JAMES FRANKEL who wrote (23734)	5/22/2007 9:04:20 AM
From: scaram(o)uche	Read Replies (2) of 52153

Message 23560773 Six of the 48 trials did not report any myocardial infarctions or deaths from cardiovascular causes and therefore were not included in the analysis (snip) I think the FDA has to get serious about defining real risk - benefit ratios for drugs, especially ones that treat large populations. Nissen is simply out of control. 28K patients, weighted to regimens that included rosiglitazone, and a difference of 14 MIs. "Risk-benefit"?? He has rock-star envy.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next